Sonova to Acquire 3.7% Ownership Stake in Sensorion

Sensorion, a clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announced that Sonova Holding AG will acquire a 3.7% ownership stake in Sensorion by way of subscription to a reserved share capital increase for total gross proceeds of €5 million (USD $6.08 million).